

Oklahoma Health Care Authority

Drug Utilization Review Board (DUR Board)

Meeting – February 11, 2026 @ 4:00pm

at the

Oklahoma Health Care Authority (OHCA)
4345 N. Lincoln Blvd.
Oklahoma City, Oklahoma 73105

NOTE: The DUR Board will meet at 4:00pm at OHCA (see address above). There will be Zoom access to this meeting; however, Zoom access will be set up in view-only mode with no voting, speaking, video, or chat box privileges. Zoom access will allow for viewing of the presentation slides as well as audio of the presentations and discussion during the meeting; however, the DUR Board meeting will not be delayed or rescheduled due to any technical issues that may arise.

AGENDA

Discussion and action on the following items:

Items to be presented by Dr. Haymore, Chairman:

1. Call to Order

A. Roll Call – Dr. Wilcox

DUR Board Members:

Dr. Cassidy Blaiss –	participating in person
Dr. Christen Ground –	participating in person
Dr. Bret Haymore –	participating in person
Dr. Bethany Holderread –	participating in person
Dr. Matt John –	participating in person
Dr. Craig Kupiec –	participating in person
Dr. Lee Muñoz –	participating in person
Dr. Edna Patatanian –	participating in person
Dr. Jennifer Weakley –	participating in person

Viewing Access Only via Zoom:

Please register for the meeting at:

https://oklahoma.zoom.us/webinar/register/WN_B7-m8jKcQWaA9HEiV7QROA

After registering, you will receive a confirmation email containing information about joining the webinar.

Or join by phone:

Dial: +1-602-753-0140 or +1-669-219-2599

Webinar ID: 928 6649 0447

Passcode: 80744869

Public Comment for Meeting:

- Speakers who wish to sign up for public comment at the OHCA DUR Board meeting may do so in writing by visiting the DUR Board page on the OHCA website at www.oklahoma.gov/ohca/about/boards-and-committees/drug-utilization-review/dur-board and completing the [Speaker Registration Form](#). Completed Speaker Registration forms should be submitted to DURPublicComment@okhca.org. Forms must be received after the DUR Board agenda has been posted and no later than 24 hours before the meeting.
- The DUR Board meeting will allow public comment and time will be limited to 40 minutes total for all speakers during the meeting. Each speaker will be given 5 minutes to speak at the public hearing. If more than 8 speakers properly request to speak, time will be divided evenly.
- Only 1 speaker per manufacturer will be allowed.
- Any speakers who sign up for public comment must attend the DUR Board meeting in person at OHCA (see above address). Public comment through Zoom will not be allowed for the DUR Board meeting.

Items to be presented by Dr. Haymore, Chairman:

2. Public Comment Forum

- A. Acknowledgement of Speakers for Public Comment

Items to be presented by Dr. Haymore, Chairman:

3. Action Item – Approval of DUR Board Meeting Minutes – See Appendix A

- A. December 10, 2025 DUR Board Meeting Minutes
- B. December 10, 2025 DUR Board Recommendations Memorandum
- C. January 14, 2026 DUR Board Recommendations Memorandum

Non-presentation items reviewed by Dr. Moss, Dr. Haymore, Chairman:

4. Update on Medication Coverage Authorization Unit – See Appendix B

- A. Pharmacy Help Desk Activity for January 2026
- B. Medication Coverage Activity for January 2026

Items to be presented by Dr. Travers, Dr. Haymore, Chairman:

5. Academic Detailing Program Update – See Appendix C

- A. Background
- B. Current Topic: Pediatric Obesity
- C. Results: Obesity-Related Care
- D. Provider Satisfaction
- E. Academic Meeting Presentation(s)
- F. Summary

Non-presentation items reviewed by Dr. Moss, Dr. Haymore, Chairman:

6. Narrow Therapeutic Index (NTI) Drug List – See Appendix D

- A. Introduction
- B. SoonerCare NTI Drug List
- C. College of Pharmacy Recommendations

Items to be presented by Dr. O'Halloran, Dr. Haymore, Chairman:

7. Action Item – Vote to Prior Authorize Doptelet® Sprinkle (Avatrombopag) and Wayrilz™ (Rilzabrutinib) and Update the Approval Criteria for the Thrombocytopenia Medications – See Appendix E

- A. Market News and Updates
- B. Wayrilz™ (Rilzabrutinib) Product Summary
- C. College of Pharmacy Recommendations

Items to be presented by Dr. DeRemer, Dr. Haymore, Chairman:

8. Action Item – Vote to Prior Authorize Andembry® (Garadacimab-gxii), Dawnzera™ (Donidalorsen), and Ekteler® (Sebetralstat) and Create a Product Based Prior Authorization (PBPA) Category for the Hereditary Angioedema (HAE) Medications – See Appendix F

- A. Market News and Updates
- B. Product Summaries
- C. Estimation of Savings
- D. College of Pharmacy Recommendations

Items to be presented by Dr. Wilson, Dr. Haymore, Chairman:

9. Action Item – Vote to Prior Authorize Atmeksi® (Methocarbamol Oral Suspension), Metaxalone 640mg Tablet, and Tanlor® (Methocarbamol 1,000mg Tablet) and Update the Approval Criteria for the Muscle Relaxant Medications – See Appendix G

- A. Market News and Updates
- B. Product Summaries
- C. Cost Comparison: Carisoprodol Products
- D. College of Pharmacy Recommendations

Items to be presented by Dr. Moss, Dr. Haymore, Chairman:

10. Action Item – Vote to Prior Authorize Imaavy™ (Nipocalimab-aahu) and Update the Approval Criteria for the Complement Inhibitors and Miscellaneous Immunomodulatory Agents – See Appendix H

- A. Market News and Updates
- B. Imaavy™ (Nipocalimab-aahu) Product Summary
- C. Cost Comparisons
- D. College of Pharmacy Recommendations

Items to be presented by Dr. O'Halloran, Dr. Haymore, Chairman:

11. Action Item – Vote to Prior Authorize Escitalopram 15mg Capsule and Raldesy™ (Trazodone Oral Solution) and Update the Approval Criteria for the Antidepressants – See Appendix I

- A. Market News and Updates
- B. Cost Comparisons
- C. College of Pharmacy Recommendations

Items to be presented by Dr. Sinko, Dr. Haymore, Chairman:

12. Action Item – Vote to Prior Authorize Keytruda Qlex™ (Pembrolizumab/Berahyaluronidase Alfa-pmpb) and Opdivo Qvantig™ (Nivolumab/Hyaluronidase-nvhy) and Update the Approval Criteria for the Skin Cancer Medications – See Appendix J

- A. Market News and Updates
- B. Product Summaries
- C. College of Pharmacy Recommendations

Items to be presented by Dr. Sinko, Dr. Haymore, Chairman:

13. Action Item – Vote to Update the Approval Criteria for the Gastrointestinal (GI) Cancer Medications – See Appendix K

- A. Market News and Updates
- B. College of Pharmacy Recommendations

Items to be presented by Dr. Sinko, Dr. Haymore, Chairman:

14. Action Item – Vote to Prior Authorize Gomekli® (Mirdametinib), Papzimeos™ (Zopapogene Imadenovec-drba), and Romvimza™ (Vimseltinib) and Update the Approval Criteria for the Non-Malignant Solid Tumor Medications – See Appendix L

- A. Market News and Updates
- B. Product Summaries
- C. College of Pharmacy Recommendations

Items to be presented by Dr. DeRemer, Dr. Haymore, Chairman:

15. Action Item – Vote to Prior Authorize Alyglo™ [Immune Globulin (IG) Intravenous (IV), Human-stwk], Asceniv™ (IGIV, Human-slra), Bivigam® (IGIV, Human), Cuvitru® [IG Subcutaneous (SC), Human], Gammaplex® (IGIV, Human), Hizentra® (IGSC, Human), Octagam® (IGIV, Human), Panzyga® (IGIV, Human-ifas) and Xembify® (IGSC, Human) – See Appendix M

- A. Cost Comparison: IGIV Products
- B. Cost Comparison: IGSC Products
- C. College of Pharmacy Recommendations

Items to be presented by Dr. Moss, Dr. Haymore, Chairman:

16. Action Item – Vote to Prior Authorize Redemplo® (Plozasiran) and Update the Approval Criteria for the Antihyperlipidemics – See Appendix N

- A. Market News and Updates
- B. Redemplo® (Plozasiran) Product Summary
- C. College of Pharmacy Recommendations

Items to be presented by Dr. Wilson, Dr. Haymore, Chairman:

17. Action Item – Vote to Prior Authorize Coxanto® (Oxaprozin 300mg Capsule), Ibuprofen 300mg Tablet, Vyscoxa™ (Celecoxib Oral Suspension), and Xifyrm™ (Meloxicam Injection) and Update the Approval Criteria for the Systemic Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) – See Appendix O

- A. Market News and Updates
- B. Product Summaries
- C. College of Pharmacy Recommendations

Items to be presented by Dr. O'Halloran, Dr. Haymore, Chairman:

18. Action Item – Vote to Prior Authorize Zepbound® (Tirzepatide) and Update the Approval Criteria for the Adiposity-Based Chronic Disease (ABCD) Medications – See Appendix P

- A. Market News and Updates
- B. Zepbound® (Tirzepatide) Product Summary
- C. Cost Comparison: MASH/NASH Medications
- D. College of Pharmacy Recommendations

Items to be presented by Dr. DeRemer, Dr. Haymore, Chairman:

19. Action Item – Vote to Prior Authorize Levofloxacin Ophthalmic Solution and Update the Approval Criteria for the Ophthalmic Antibiotic Medications – See Appendix Q

- A. Market News and Updates
- B. College of Pharmacy Recommendations

Items to be presented by Dr. Moss, Dr. Haymore, Chairman:

20. Action Item – Vote to Prior Authorize Estradiol 0.06% Gel (Generic EstroGel®) and Lynkuet™ (Elinzanetant) and Update the Approval Criteria for the Vasomotor Symptom (VMS) Medications – See Appendix R

- A. Market News and Updates
- B. Product Summaries
- C. Cost Comparisons
- D. College of Pharmacy Recommendations

Items to be presented by Dr. Wilson, Dr. Haymore, Chairman:

21. Action Item – Vote to Prior Authorize MoviPrep® [Polyethylene Glycol 3350 (PEG 3350)/Sodium Sulfate/Sodium Chloride/Potassium Chloride/Sodium Ascorbate/Ascorbic Acid for Oral Solution] and Update the Approval Criteria for the Bowel Preparation Medications – See Appendix S

- A. Market News and Updates
- B. College of Pharmacy Recommendations

Items to be presented by Dr. DeRemer, Dr. Haymore, Chairman:

22. Action Item – Vote to Prior Authorize Aceon® (Perindopril), Arbli™ (Losartan Oral Suspension), Bisoprolol Fumarate 2.5mg Tablet, Hemiclor™ (Chlorthalidone 12.5mg Tablet), Inzirqo™ [Hydrochlorothiazide (HCTZ) Oral Suspension], Javadin™ (Clonidine Oral Solution), Lopressor® (Metoprolol Tartrate Oral Solution), and Univasc® (Moexipril) and Update the Approval Criteria for the Antihypertensive Medications – See Appendix T

- A. Market News and Updates
- B. Cost Comparisons
- C. College of Pharmacy Recommendations

Items to be presented by Dr. Wilson, Dr. Haymore, Chairman:

23. Action Item – Annual Review of Cholestatic Liver Disease and Bile Acid Disorder Medications – See Appendix U

- A. Current Prior Authorization Criteria
- B. Utilization of Cholestatic Liver Disease and Bile Acid Disorder Medications
- C. Prior Authorization of Cholestatic Liver Disease and Bile Acid Disorder Medications
- D. Market News and Updates
- E. College of Pharmacy Recommendations
- F. Utilization Details of Cholestatic Liver Disease and Bile Acid Disorder Medications

Items to be presented by Dr. O'Halloran, Dr. Haymore, Chairman:

24. Action Item – Annual Review of Anticonvulsants – See Appendix V

- A. Current Prior Authorization Criteria
- B. Utilization of Anticonvulsants
- C. Prior Authorization of Anticonvulsants
- D. Market News and Updates
- E. College of Pharmacy Recommendations
- F. Utilization Details of Anticonvulsants

Items to be presented by Dr. Wilson, Dr. Haymore, Chairman:

25. Action Item – Annual Review of Insomnia Medications – See Appendix W

- A. Current Prior Authorization Criteria
- B. Utilization of Insomnia Medications
- C. Prior Authorization of Insomnia Medications

- D. Market News and Updates
- E. College of Pharmacy Recommendations
- F. Utilization Details of Insomnia Medications

Items to be presented by Dr. DeRemer, Dr. Haymore, Chairman:

26.30-Day Notice to Prior Authorize Cardamyst™ (Etripamil Nasal Spray) – See Appendix X

- A. Introduction
- B. Cardamyst™ (Etripamil Nasal Spray) Product Summary
- C. College of Pharmacy Recommendations

Items to be presented by Dr. Moss, Dr. Haymore, Chairman:

27. Annual Review of Anti-Migraine Medications and 30-Day Notice to Prior Authorize Brekiya® [Dihydroergotamine (DHE) Autoinjector) – See Appendix Y

- A. Current Prior Authorization Criteria
- B. Utilization of Anti-Migraine Medications
- C. Prior Authorization of Anti-Migraine Medications
- D. Market News and Updates
- E. Cost Comparison: DHE Products
- F. College of Pharmacy Recommendations
- G. Utilization Details of Anti-Migraine Medications

Items to be presented by Dr. DeRemer, Dr. Haymore, Chairman:

28. Annual Review of Pulmonary Hypertension Medications and 30-Day Notice to Prior Authorize Yutrepia™ (Treprostинil Powder for Inhalation) – See Appendix Z

- A. Current Prior Authorization Criteria
- B. Utilization of Pulmonary Hypertension Medications
- C. Prior Authorization of Pulmonary Hypertension Medications
- D. Market News and Updates
- E. Yutrepia™ (Treprostинil Powder for Inhalation) Product Summary
- F. College of Pharmacy Recommendations
- G. Utilization Details of Pulmonary Hypertension Medications

Non-presentation items reviewed by Dr. O'Halloran, Dr. Haymore, Chairman:

29. Annual Review of Crenessity® (Crinecerfont) – See Appendix AA

- A. Current Prior Authorization Criteria
- B. Utilization of Crenessity® (Crinecerfont)
- C. Prior Authorization of Crenessity® (Crinecerfont)
- D. Market News and Updates
- E. College of Pharmacy Recommendations
- F. Utilization Details of Crenessity® (Crinecerfont)

Non-presentation items reviewed by Dr. DeRemer, Dr. Haymore, Chairman:

30. Annual Review of Kebilidi™ (Eladocagene Exuparvovec-tneq) – See Appendix AB

- A. Current Prior Authorization Criteria
- B. Utilization of Kebilidi™ (Eladocagene Exuparvovec-tneq)
- C. Prior Authorization of Kebilidi™ (Eladocagene Exuparvovec-tneq)
- D. College of Pharmacy Recommendations

Non-presentation items reviewed by Dr. Moss, Dr. Haymore, Chairman:

31. U.S. Food and Drug Administration (FDA) and Drug Enforcement Administration (DEA) Updates – See Appendix AC

Items to be presented by Dr. Adams, Dr. Haymore, Chairman:

32. Future Business* (Upcoming Product and Class Reviews)

- A. Dry Eye Disease (DED) Medications
- B. Fesilty (Fibrinogen, Human-chmt)
- C. Granulocyte Colony-Stimulating Factors (G-CSFs) and Stem Cell Mobilizers
- D. Growth-Related Disorder Medications
- E. Hemophilia Medications
- F. Leukemia and Lymphoma Medications
- G. Muscular Dystrophy Medications
- H. Topical Antibiotic Products
- I. Waskyra (Etuvetidigene Autotemcel)

*Future product and class reviews subject to change.

33. Adjournment

NOTE: An analysis of the atypical [Aged, Blind, and Disabled (ABD)] patient subgroup of the Oklahoma Medicaid population has been performed pertaining to all recommendations included in this DUR Board meeting packet to ensure fair and knowledgeable deliberation of the potential impact of the recommendations on this patient population.

NOTE: Oklahoma Medicaid transitioned from a fee-for-service (FFS) pharmacy benefit to a managed care pharmacy benefit for most members on April 1, 2024. At that time, the majority of SoonerCare members were transitioned to one of the three managed care SoonerSelect plans: Aetna, Humana, or Oklahoma Complete Health. SoonerSelect data has been provided to the College of Pharmacy and has been used in analyses throughout this DUR Board meeting packet. The data included in this DUR Board meeting packet combines FFS and managed care utilization data. The managed care utilization and prior authorization (PA) data reported in this packet is based solely on the data provided by the SoonerSelect plans. SoonerSelect PA data only includes medications billed as pharmacy claims (NDC) and does not include those billed as medical claims (HCPCS), where applicable.